demonstrated that treatment of non-small cell lung cancer (NSCLC) patient tumours with the PPARγ ligand troglitazone conferred anti-proliferative effects due to G0/G1 cell cycle arrest and reduction in cyclin D/E expression (145). The gene discussed is PPARG; the disease is non-small cell lung carcinoma.